Neurolixis Inc. announced today that the European Commission approved its application for Orphan Medicinal Product Designation for NLX-101 in the treatment of Rett syndrome (see European Commission register). Rett syndrome is a rare genetic disorder that affects 1 female in about 10 000 and causes extensive and debilitating symptoms. NLX-101 targets the breathing difficulties that are commonly experienced by Rett syndrome patients. Orphan Medicinal Product designation provides a ten-year period of European Union marketing exclusivity as well as other benefits. 

Read the full press announcement:  .